Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest Down 72.9% in May

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 29,500 shares, a decrease of 72.9% from the April 30th total of 108,900 shares. Approximately 0.0% of the company's stock are short sold. Based on an average daily volume of 441,800 shares, the short-interest ratio is presently 0.1 days.

Daiichi Sankyo Stock Down 1.6%

DSNKY stock traded down $0.44 during trading on Friday, reaching $26.61. The stock had a trading volume of 121,705 shares, compared to its average volume of 277,258. Daiichi Sankyo has a one year low of $20.92 and a one year high of $42.48. The company has a quick ratio of 2.11, a current ratio of 2.77 and a debt-to-equity ratio of 0.06. The company's 50 day moving average is $24.40 and its two-hundred day moving average is $25.98. The company has a market capitalization of $50.78 billion and a price-to-earnings ratio of 30.94.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported $0.30 earnings per share (EPS) for the quarter. Daiichi Sankyo had a net margin of 13.62% and a return on equity of 14.53%. The business had revenue of $3.40 billion during the quarter. Equities research analysts forecast that Daiichi Sankyo will post 0.73 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.